Scientists at Tel Aviv University have developed a groundbreaking experimental therapy for spinal cord injuries that dramatically reduced nerve damage and enhanced motor function recovery in laboratory animal studies. The research team believes this innovative approach could revolutionize treatment methods for both spinal cord and traumatic brain injuries.
The research, conducted by the Gray Faculty of Medical & Health Sciences at Tel Aviv University and published recently in the journal Inflammation and Regeneration, targeted the prevention of secondary damage that occurs following the original spinal cord trauma. The scientists reported that their treatment decreased inflammation, reduced scar tissue development, and prevented nerve cell deterioration while enhancing the restoration of movement and walking capabilities.
“This study presents an innovative therapeutic approach that significantly reduces early nerve cell damage after spinal cord injury and improves functional recovery. Treated animals achieved up to 80% recovery of motor function, highlighting the therapy’s potential to dramatically improve outcomes after injury,” the researchers said.
The research team was headed by Dr. Angela Ruban from the Stanley Steyer School of Health Professions at the Gray Faculty of Medical & Health Sciences and the Sagol School of Neuroscience, working alongside Dr. Yona Goldshmit and students Josef Levin, Rosemary Lavender, Alexander Yakovchuk, Evgeny Banyas, and Ruth Baltovska. A CRO independently confirmed the results as part of NeuroHagana’s preclinical development program under Dr. Amit Benbenishty’s leadership.
According to the researchers, spinal cord trauma causes a quick accumulation of glutamate, a brain chemical that can lead to further nerve cell destruction, inflammation, deterioration, and tissue scarring. Their innovative therapy operates by eliminating excessive glutamate from the blood circulation within the initial hours following trauma.
During animal experiments, treated subjects regained up to 80% of typical motor abilities two months post-treatment, while untreated animals recovered only approximately 30%. The scientists noted that the therapy showed effectiveness when given as late as 8 hours post-injury and could be administered by emergency personnel through a straightforward intravenous injection.
Dr. Ruban indicated the results suggest it might be feasible to halt the secondary damage cascade following injury, while Dr. Goldshmit noted the technique could potentially apply to stroke and traumatic brain injuries as well. The research team is currently investigating its possible application for blast-related head trauma stemming from the Oct. 7 attacks and subsequent conflict.
